3 Biotech Stocks to Monitor Right Now

Biotech stocks NVAX, INSM, and MRNA have been red-hot lately

Managing Editor
Jun 10, 2024 at 3:33 PM
facebook X logo linkedin


Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month. Going off of that, we're profiling XBI's three biggest holdings, Novavax Inc (NASDAQ:NVAX)Insmed Inc. (NASDAQ:INSM), and Moderna Inc (NASDAQ:MRNA)

NVAX is down 12.4% to trade at $15.91 today, with no specific catalyst to explain the gap lower, and on track for its worst single-session loss since Feb. 28. Thanks to the Sanofi (SNY) deal earlier in May, NVAX is up 226% in 2024. The security fresh off a June 6, 52-week high of $23.85 as well.

INSM is up 6.7% to trade at $60.64, and earlier hit a record high of $60.47, thanks to a price-target hike to $85 from $75 at Leerink. The shares are up 93% so far in 2024, and have come a long way since this year's May 24 low of $21.92.

Moderna stock is 1.7% lower to trade at $147.77 at last check, despite phase three trial data that indicated its combined Covid-19 and flu shot provided better protection than its standalone shots. MRNA is up 49.2% in 2024, forming a bull flag pattern on the charts.

Biotech Stocks

 

 

Unlock Weekend Profits with Chris Prybal's Favorite Strategy Up +487.5% in 2024

With the markets going left, right, and sideways, you need to have a plan now more than ever. 

Expert Trader Chris Prybal is no stranger to volatility, and has mastered finding big stock rallies while other traders aren't looking over the weekend. Rallies that produced gains like +207% on RTX calls, +236% on MARA calls, and +238% on NET calls.

A few simple moves on Sunday at 7pm could be the “Secret Sauce” your portfolio needs to not just stay afloat, but make unprecedented gains in this turbulent market.


Don’t sit on the sidelines, beat the market with Chris Prybal's strategy. Join him now!

 

 
 
 


 
 

Rainmaker Ads CGI